** German drug containment and delivery systems maker Schott Pharma 1SXP.DE is upgraded to "buy" from "neutral" by UBS, which says two headwinds are abating
** The analyst expects the sector-wide vial destocking following the COVID pandemic to abate by mid 2025 at the latest noting positive developments in order intake
** Following last year's order cancellations the broker removes about EUR 90 million of mRNA polymer syringe sales from its estimates
** However, UBS still sees potential for growth in the glass syringe business on the back of capacity additions to more than offset the reduction in mRNA polymer syringe sales
** UBS says Schott trades at about a 30% discount to peer Stevanato STVN.N despite similar sales and profits three year compounded annual growth rates
** Out of 12 analysts that cover SCHOTT Pharma AG & Co KgaA, five rate the stock "strong buy" or "buy," four rate "hold" and three rate the stock "strong sell" or "sell"
(Reporting by Simon Ferdinand Eibach)
((Simonferdinand.eibach@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。